Jefferies Thomas Wei defended Neurocrine Biosciences (NASDAQ: NBIX) after the company's VMAT2 inhibitor NBI-98854 failed to show a significant improvement ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE